Beyza Cengiz

Beyza Cengiz

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
BCBeyza Cengiz
Beyza Cengiz
MSMustafa Ünal Sayılır
Mustafa Ünal Sayılır
NZNur Yıldız Zengin
Nur Yıldız Zengin
ÖKÖykü Nehir Küçük
Öykü Nehir Küçük
ASAbdullah Ruhi Soylu
Abdullah Ruhi Soylu
Background: The increase in the coronavirus disease 2019 (COVID-19) vaccination rates in Turkey and in the world plays a key role in reducing the number of deaths and cases from COVID-19. Investigating the underlying causes of COVID-19 vaccine hesitations seems to be a guide in reducing the negative effects of the pandemic. Methods: We analyzed the correlations between double COVID-19 vaccination rates of all cities in Turkey between 1 September 2021 and 1 February 2022 and their per capita income values and their education level percentages. Results: Overall, there was a negative correlation between the vaccination rates of cities and the percentages of illiterate, literate without a diploma, and secondary school graduates for both genders. However, there was a positive correlation between city vaccination rates and the percentages of primary school and college graduates. City income values per capita values were positively correlated with double vaccination rates of cities. Conclusion: Our findings suggest that not only low levels of education, but also interruption of education at some point make a significant contribution to vaccination hesitancy and ultimately to vaccination levels. In order to end the pandemic and reach a sufficient percentage of vaccines, it may be necessary to address some special groups and raise awareness of these groups about vaccination.

12 June 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
KEKazumi ECKENSTEIN
Kazumi ECKENSTEIN
BCBeyza Cengiz
Beyza Cengiz
MCMatthew E.K. Chang
Matthew E.K. Chang
JCJessie May Cartier
Jessie May Cartier
MFMark R Flory
Mark R Flory
GTGeorge V Thomas
George V Thomas
Background/Objectives: Renal cell carcinoma (RCC) exhibits distinctive metabolic vulnerabilities that may be therapeutically targeted. This study investigates how tigecycline, an FDA-approved antibiotic that inhibits mitochondrial translation, affects RCC cells and explores potential combinatorial approaches to enhance its efficacy. Methods: We employed comprehensive metabolomic profiling, subcellular proteomics, and functional assays to characterize the effects of tigecycline on RCC cell lines, patient-derived organoids, and xenograft models. The synergistic potential of tigecycline with the histone deacetylase inhibitor entinostat was evaluated using combination index analysis. Results: Tigecycline selectively inhibited mitochondrial translation in RCC cells, reducing mitochondrially-encoded proteins while sparing nuclear-encoded components, profoundly disrupting mitochondrial bioenergetics and reducing tumor growth in xenograft models. Subcellular proteomic analyses revealed that tigecycline treatment triggered a significant accumulation of multiple histone variants concurrent with cell cycle arrest. Based on this discovery, combined treatment with tigecycline and entinostat demonstrated remarkable synergism across RCC cell lines and patient-derived. Conclusions: Our findings identify a promising therapeutic opportunity by targeting the crosstalk between mitochondrial function and epigenetic homeostasis in RCC, with the potential for rapid clinical translation given the established pharmacological profiles of both agents.

20 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
WCWesley H. Chou
Wesley H. Chou
LLLucy Lawrence
Lucy Lawrence
ENEmma Neham
Emma Neham
SAShreeram Akilesh
Shreeram Akilesh
AMAmy E. Moran
Amy E. Moran
GTGeorge V Thomas
George V Thomas
Background and Objective: Patients with stage III clear cell renal cell carcinoma (ccRCC) have a high risk for disease recurrence post-nephrectomy. To mitigate overtreatment, there is a pressing need to determine who benefits from immune checkpoint inhibition (ICI) around the time of surgical resection. We performed digital spatial analysis of both gene and protein expression in stage III ccRCC tumors, some of which had preoperative ICI exposure. Methods: Nephrectomy specimens from stage III ccRCC patients were analyzed using the Nanostring GeoMx Digital Spatial Profiler. Differential expression analysis was performed and validated using NCT02210117 trial data to identify genes associated with both ICI and clinical response. A gene score was then generated to predict overall survival in patients from The Cancer Genome Atlas (TCGA). Key Findings and Limitations: In a small cohort of 19 patients, RNA expression significantly differed based on preoperative ICI exposure and recurrence status—CD8+ effector and central-memory T-cell signatures were less prevalent in the treatment-naïve with recurrence group. Three out of four patients with preoperative immune checkpoint inhibition recurred. External validation yielded a four-gene set (GZMK, GZMA, ITGAL, and IL7R), where higher expression levels predicted better overall survival in the TCGA cohort (p = 0.005). Conclusions and Clinical Implications: Preoperative ICI favorably altered the tumor microenvironment to resemble that of treatment-naïve patients without recurrence but did not translate to improved survival. Upon external validation, the genes GZMK, GZMA, ITGAL, and IL7R were modifiable with ICI and associated with improved overall survival. Further investigation is needed to assess if patients with low baseline expression of these genes may benefit from ICI around the time of surgery.

2 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
WCWesley Chou
Wesley Chou
LLLucy Lawrence
Lucy Lawrence
ENEmma Neham
Emma Neham
SAShreeram Akilesh
Shreeram Akilesh
AMAmy E. Moran
Amy E. Moran
GTGeorge V Thomas
George V Thomas
Purpose: Patients with stage III clear cell renal cell carcinoma are at high risk for recurrence after nephrectomy. To mitigate overtreatment, there is a pressing clinical need to determine which patients benefit most from perioperative immune checkpoint inhibition. We performed a multimodal digital spatial analysis of gene and protein expression in stage III primary renal cell carcinomas, a subset of which had preoperative immune checkpoint inhibition exposure. Materials and Methods: Surgically resected tumors from stage III clear cell renal cell carcinoma patients were analyzed using the Nanostring GeoMx Digital Spatial Profiler. Differential expression analysis was performed and validated using NCT02210117 trial data to identify genes associated with immune checkpoint blockade and clinical response. A gene score was then generated to predict overall survival in patients from The Cancer Genome Atlas. Results: Among 19 patients, RNA expression significantly differed based on preoperative immune checkpoint blockade and recurrence – CD8+ effector and central-memory T-cell signatures were less prevalent in the treatment-naïve with recurrence group. Three out of four patients with preoperative immune checkpoint inhibition had recurrence. External validation yielded a 4-gene set ( GZMK, GZMA, ITGAL , and IL7R ); higher gene expression levels predicted better overall survival in The Cancer Genome Atlas cohort (p=0.005). Discussion: Preoperative immune checkpoint blockade favorably altered the tumor microenvironment to resemble that of treatment-naïve patients without recurrence. However, this did not translate to better clinical outcomes. On external validation, the genes GZMK, GZMA, ITGAL , and IL7R were modifiable with immune checkpoint inhibition and associated with improved survival. Further investigation to assess if patients with low baseline expression of these genes may particularly benefit from perioperative immune checkpoint blockade is warranted.

Verified
Journal Article
Open access
PDF file
MAMarcela Riveros Angel
Marcela Riveros Angel
DLDavid Loeffler
David Loeffler
ACAhmad Charifa
Ahmad Charifa
RSRyan Barry Sinit
Ryan Barry Sinit
TATaylor Amery
Taylor Amery
GTGeorge V Thomas
George V Thomas
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular entry is facilitated by transmembrane protease serine 2 (TMPRSS2), which is regulated by the androgen receptor (AR). Androgen deprivation therapy (ADT), widely used in prostate cancer treatment, may potentially modulate TMPRSS2 expression, affecting SARS-CoV-2 infection susceptibility and severity. We evaluated the impact of ADT on pulmonary TMPRSS2 expression in prostate cancer patients and analyzed differences in expression patterns associated with specific ADT regimens. We examined TMPRSS2 immunohistochemical expression in lung tissue from 20 consecutive autopsy cases of men with prostate cancer (6 receiving ADT at time of death), compared with non-ADT prostate cancer patients and age-matched women controls. Histoscores were calculated by assessing the percentage and intensity of pneumocyte TMPRSS2 expression. Prostate cancer patients receiving ADT showed significantly reduced pulmonary TMPRSS2 expression compared to non-ADT patients (mean histoscores: 152.7 vs. 225.0, p = 0.037) and age-matched women controls (mean histoscores: 152.7 vs. 238.0, p = 0.024). Direct AR antagonists (apalutamide, bicalutamide) produced greater TMPRSS2 suppression than Gonadotropin-Releasing Hormone modulators or androgen biosynthesis inhibitors. No significant correlation was observed between the TMPRSS2 expression and Gleason score, PSA levels, or underlying lung pathology. Our findings demonstrate that ADT significantly reduces pulmonary TMPRSS2 expression, with direct AR antagonists showing the strongest effect. This suggests a potential mechanistic explanation for differential COVID-19 susceptibility and provides a rationale for investigating AR-targeted therapies as potential protective interventions against SARS-CoV-2 infection severity.